Table 2.
Effect on electrocardiographic parameters against alloxan-induced diabetic complications.
| Treatment | Heart rate (beats/min) | QRS duration (ms) | QT interval (ms) | RR interval (ms) | ST interval (ms) |
|---|---|---|---|---|---|
| Normal control | 183.12 ± 2.30 | 120.93 ± 1.73 | 120.78 ± 1.73 | 192.2 ± 2.30 | 57.01 ± 1.15 |
| Diabetic control | 247.77 ± 2.88b | 203.49 ± 2.30b | 244.49 ± 2.88b | 314.83 ± 2.88b | 92.34 ± 1.73b |
| TOL | 232.7 ± 2.30b,c | 164.01 ± 2.30b,e | 164.23 ± 1.73b,e | 248.15 ± 2.30b,e | 76.59 ± 1.45b,e |
| PJ | 221.51 ± 2.88b,e | 181.77 ± 1.73b,e | 155.95 ± 1.73b,e | 291.27 ± 2.80b,e | 82.25 ± 1.73b,d |
| TOL + PJ | 200.42 ± 2.30a,e,f | 129.14 ± 1.73e,f | 128.45 ± 1.73e,f | 224.26 ± 2.30b,e,f | 61.56 ± 1.73e,f |
All values are mean ± SEM, n = 8.
ap < 0.01 and bp < 0.001, when compared to normal control; cp < 0.05, dp < 0.01, and ep < 0.001 when compared to diabetic control; and fp < 0.001 when compared to the group treated with TOL alone.
PJ, pomegranate juice; QRS, ; QT, ; RR, ; SEM = standard error of the mean; ST, ; TOL, tolbutamide.